The pharmaceutical industry’s former dependence on blockbuster drugs has evolved to focus on developing drugs that address the unmet needs of smaller patient populations. These niche drugs are most commonly found in the form of biopharmaceuticals, which have accounted for an ever-increasing share of new drug approvals over the last ten years, from a low of 10 percent to a high of 27 percent.1 By 2022, 50 percent of the top 100 products are expected to come from biopharmaceuticals.2